SPOTLIGHT: ProStrakan float flounders

The UK's ProStrakan has cut its stock valuation for the fifth time, seeking £40 million. Last May, ProStrakan outlined plans to raise £100 million. A string of European biotechs has suspended plans to go public in recent weeks amid signs of a chilly market response. Release

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.